Cutrer to step down as NAS president/CEO

Nov 2, 2006

North American Scientific (NAS) founder Michael Cutrer will step down as president and CEO of the Chatsworth, CA, radiation therapy firm to become executive vice president and chief technology officer of the company.

Cutrer said his decision is based on a desire to concentrate his efforts on the company's breast brachytherapy program and other future radiation therapy projects.

The board of directors has formed a committee to immediately begin a search for Cutrer's successor as president and CEO.

By AuntMinnie.com staff writers
November 3, 2006

Related Reading

NAS gets nomosSTAT install, October 19, 2006

Losses rise, revenues down in NAS' Q3, September 8, 2006

NAS nets FDA nod, July 25, 2006

NAS back in compliance with Nasdaq, June 29, 2006

NAS revenues dip in Q2, June 8, 2006

Copyright © 2006 AuntMinnie.com

Latest in Radiation Oncology/Therapy
Breast Cancer3 400
ASTRO: Shorter radiation course safe for breast reconstruction
October 2, 2024
Lung Cancer
ASTRO: Timing key to adding immunotherapy to chemoradiation
October 1, 2024
Black Patient
ASTRO: Black patients voice distrust in medical research
September 30, 2024
Prostate Imaging
ASTRO: IMRT and proton therapy equally effective for prostate cancer
September 30, 2024
Related Stories
187x200 Am Logo
Companies
AuntMinnie.com
2006 09 29 14 21 16 706
Radiation Oncology/Therapy
Optimizing the method, moment for reconstructing the irradiated breast
2002 03 13 15 53 59 706
Radiation Oncology/Therapy
Imaging adds precision as IGRT sweeps radiation oncology
2003 06 09 16 56 16 706
Radiation Oncology/Therapy
IMRT to 4D radiotherapy rely on QA for accuracy
More in Radiation Oncology/Therapy
ASTRO: Shorter radiation course safe for breast reconstruction
By Amerigo Allegretto
Research presented at the ASTRO annual meeting shows that a shorter course of postmastectomy radiation combined with breast reconstruction is safe.
October 2, 2024
Breast Cancer3 400
ASTRO: Timing key to adding immunotherapy to chemoradiation
By Amerigo Allegretto
Timing may be key when adding immunotherapy to chemoradiation for lung cancer treatment.
October 1, 2024
Lung Cancer
ASTRO: Black patients voice distrust in medical research
By Will Morton
Spiritual beliefs and a distrust of clinical research may partly explain why Black patients choose not to participate in cancer trials.
September 30, 2024
Black Patient
ASTRO: IMRT and proton therapy equally effective for prostate cancer
By Will Morton
Intensity-modulated radiation therapy (IMRT) and proton therapy offer equally high quality of life and tumor control for people with prostate cancer.
September 30, 2024
Prostate Imaging
ASTRO: Lu-177 dotatate shows promise for treating meningioma patients
By Kate Madden Yee
A radiopharmaceutical therapy that lengthens progression-free survival for patients with neuroendocrine cancer could help treat meningioma sufferers.
September 30, 2024
Brain
ASTRO: Brain cancer patients treated by radiation recoup cognitive function
By Kate Madden Yee
Patients with brain metastases who experience cognitive side effects after radiation therapy appear to eventually regain cognitive function.
September 30, 2024
Brain Puzzle Dementia
Bone marrow disorders associated with SARs in Lutathera patients
By Will Morton
Pretreatment bone marrow disorders may predict which patients are at risk for severe adverse reactions (SARs) when treated with lutetium-177 DOTATATE.
July 15, 2024
2024 07 11 Sa Rs Patients Lu 177 Dotatate Voter
The rise of theranostics: Part 5 -- Advice from center administrators
By Liz Carey
Want to launch theranostics at your hospital and cancer center? An SNMMI 2024 session provided key planning steps.
July 12, 2024
Nuclear medicine technologist and theranostics practice administrator Dmitry Beyder (left) and Vikas Prasad, MD, PhD (right), lead the theranostics center at Barnes-Jewish Hospital/Washington University in Saint Louis, MO. Image courtesy of Washington University.
Risk factor for blood disorders identified in PRRT patients
By Will Morton
Researchers have identified a risk factor that may be involved in potentially fatal blood disorders in patients undergoing peptide receptor radionuclide therapy (PRRT).
July 12, 2024
Cytopenia
ASTRO chair responds to proposed cuts in 2024 MPFS
By AuntMinnie.com staff writers
ASTRO has issued a statement from Jeff Michalski, MD, in response to continued reimbursement declines in the proposed 2025 MPFS.
July 11, 2024
Capitol Hill Government 400
ASTRO lobbies for new radiation therapy payment bill
By Will Morton
AuntMinnie.com spoke with Casey Chollet-Lipscomb, MD, who joined radiation oncologists from around the U.S. to lobby for a new payment model for radiation therapy.
May 21, 2024
Casey Chollet
AI chatbots deemed ‘empathetic’ to cancer patients
By Will Morton
AI chatbots can generate high-quality, empathetic, and readable responses to cancer patients' questions compared with physicians.
May 16, 2024
Chatgpt
Page 1 of 462
Next Page